

Corporate Profile

Become a global specialty pharmaceutical company





Our mission statement **Commitment to Life**

Countless precious lives surround us.

Brought into this world, blessed, raised with loving care – full of dreams,
happiness as the goal of life.

Deeply instill in us, and know that what we work for – the most precious presence of all on this planet.
Infinite possibilities for us, a pharmaceutical company.

Believe in ourselves, believe in our power, believe in what we have built together.

Not a large company, but with qualities like none other.

History so unique we can be proud of, technology unmatched,

And superior human beings that cannot be found elsewhere.

Be brave; do not shy away from challenges. Have passion; break away from the norm.

Innovation is not just about growth – but instead a leap towards the future, a grand growth with wings.

Wings never to be given to those who settle for the status-quo.

Don't just make medicine. Make people smile, bring light to their lives.


How strongly one longs to live. How deeply one is loved by their loved ones.

How sincerely one desires to help the one life they dedicate themselves to in the field of medicine.

Stay receptive, sharpen your sensitivities.

Let us become the top company in the world who cares the most for life.

Strength is not what saves the world. A caring heart is what the world calls for.



Strive to become a superb team.

One human being, excellent or not, is ever so powerless, as a power of one, mistakes, even a possibility.

Show the world the excellence of coming together. Amazing results, when we become one.

Be driven. Think of those fighting for their lives every day.

Their strong devotion to life speaks to our hearts.

Hurry – do not scurry, but we must not stand still. Stay sincere, always – may that be our vow.

We make medicine. This is, our walk of life.

Work, can bring happiness. Remember this, always.

Born on this planet in various parts of the globe, passing through life in different ways,

And like a miracle we found one another – our jobs, our team, our company.

Know this, and be fulfilled, always.

Be thankful of what you have, pour your heart and soul into the mission you were given,

Be proud of your work, the work to save precious lives.

We are, each and everyone of us, Kyowa Hakko Kirin.

Taking the walk of life, one life at a time.

Kyowa Hakko Kirin aims to be a global specialty pharmaceutical company contributing to the health and comfort of people around the world through biotechnologies.



In the core fields of oncology, nephrology and immunology, Kyowa Hakko Kirin leverages leading-edge biotechnologies centered on antibody technologies to continually discover innovative new drugs and to develop and market those drugs worldwide. In this way, we are working to realize our vision of becoming a Japan-based global specialty pharmaceutical company contributing to human health and well-being worldwide.


Our mission is to consistently respond earnestly to the needs of patients suffering from diseases for which no effective treatments are available, their families, and the healthcare professionals who are fighting the diseases at the front line.

By continually discovering innovative new drugs, we hope to bring smiles to all people who are battling disease. With such aspirations, we thoroughly discussed what we should value, which we defined as a "Commitment to Life." We reflect this commitment in our work every day as we continue to take on new challenges.

The Kyowa Hakko Kirin Group has launched a new medium-term business plan for the three-year period from 2013 through 2015. The theme of the plan is "Become a global specialty pharmaceutical company." We will quickly implement various measures in line with the key strategies of this plan, aiming for global growth with a unique business model that integrates our various businesses to capitalize on our strengths, generate synergies and provide the flexibility needed to respond to changes in the external environment. Kyowa Hakko Kirin Co., Ltd., the core company of the Group, focuses on creating innovative drugs; Kyowa Medex Co., Ltd. contributes to personalized medicine in the diagnostic reagents business; FUJIFILM KYOWA KIRIN BIOLOGICS Co., Ltd. is working to provide biosimilars using Kyowa Hakko Kirin's manufacturing capabilities; and Kyowa Hakko Bio Co., Ltd. is engaged in a range of business activities such as supplying the amino acids needed in antibody production and manufacturing active pharmaceutical ingredients.

Becoming a global specialty pharmaceutical company also means we must earn the trust of society as a corporate group by meeting social needs. We will do more than fulfill social responsibilities such as maintaining transparency, fairness, compliance and coexistence with local communities; we will focus our efforts on being a life-sciences company trusted by our broad range of stakeholders.

I would like to ask our valued stakeholders for their continued support.



Nobuo Hanai
President and Chief Executive Officer

Become a global specialty pharmaceutical company

Our business vision is to be a Japan-based global specialty pharmaceutical company contributing to human health and well-being worldwide through innovative drug discovery and global commercialization, driven by cutting-edge antibody technologies mainly in the core therapeutic areas of oncology, nephrology and immunology.

The Kyowa Hakko Kirin Group formulated the Medium-Term Business Plan – 2013 to 2015 to achieve its vision. The Group is now in a new stage in its drive toward becoming a global specialty pharmaceutical company. Over the next three years, we will steadily build the foundation for making the leap to that goal by executing three basic strategies: maximize the value of our business in Japan, expand our business base in the United States, Europe and Asia, and improve revenue and profitability in our Bio-Chemicals business.

Roadmap toward Achieving Our Vision




Leveraging our strengths centered on a unique business model and antibody technologies

Building on our strengths – proprietary antibody technologies and a unique portfolio of businesses composed of the core new drug development business along with biosimilar, diagnostic reagent and biochemical businesses – we will follow category-based strategies in the therapeutic areas of nephrology, oncology, immunology/allergy and the central nervous system while leveraging our worldwide network and management foundation to become a global specialty pharmaceutical company.

1 Therapeutic Antibody

Using cutting-edge biotechnology

Kyowa Hakko Kirin is using its core proprietary technology POTELLIGENT® in strategic alliances with other companies to rapidly expand its antibody business.



2 Product Development

Accelerating research and development and maximizing product value

We are executing a category-based strategy in the therapeutic areas of nephrology, oncology, immunology/allergy and central nervous system. We are also strengthening cooperation from research and development to manufacturing and sales to accelerate research and development and maximize product value.



3 Network

Expanding our global business platform from drug discovery to development and marketing

The operations of our global drug discovery research network and our bases driving development in the United States and Europe are integrated. We are expanding marketing channels in the United States and Europe and pursuing business strategies tailored to local market conditions in Asia.



4 Management Foundation

Creating an organization appropriate for a global specialty pharmaceutical company

We are creating an organization and corporate culture appropriate for a global specialty pharmaceutical company, and fulfilling our social responsibilities as a life-sciences company in good faith.




We create new pharmaceuticals with antibody technology backed by cutting-edge biotechnology.

A core strength of Kyowa Hakko Kirin, therapeutic antibodies are designed to use the immune system, the body's natural defense mechanism, as a medicine to treat diseases. We are establishing proprietary antibody technologies to move our antibody business forward with strategic alliances as well as for our own new drug development.

ADCC enhanced antibody activity technology enables more effective elimination of target cells

POTELLIGENT®



A key feature of POTELLIGENT®, a proprietary Kyowa Hakko Kirin technology, is its ability to remarkably increase antibody-dependent cellular cytotoxicity (ADCC)¹ activity by reducing the amount of fucose in the sugar chain of antibodies. Animal and other testing has shown that POTELLIGENT® dramatically enhances effectiveness in attacking cancer cells and other targets compared to conventional therapeutic antibodies.

Developing POTELLIGENT® Technology into an Antibody Business


To maximize the value of the therapeutic antibodies in our pipeline, we are taking multiple approaches to development, including out-licensing candidates at early stages and concluding antibody technology licensing contracts with other companies. Having multiple approaches allows us to accelerate commercialization of therapeutic antibodies to develop a world-class therapeutic antibody business while providing new drugs for diseases that do not yet have effective treatments. As of January 31, 2013, we have concluded POTELLIGENT® technology licensing contracts with 16 companies, including leading global therapeutic antibody companies and major pharmaceutical companies.

1. An immune response that mobilizes natural killer cells and monocytes and other leukocytes to destroy cancer cells and other target cells tagged with antibodies

CDC enhanced antibody activity technology multiplies the efficacy of antibody drugs

COMPLEGENT®

Kyowa Hakko Kirin developed the complement-dependent cytotoxicity (CDC)² enhanced antibody activity technology COMPLEGENT® to increase the activity of therapeutic antibodies, just as POTELLIGENT® is designed to do. The combined use of COMPLEGENT® and POTELLIGENT® technologies will allow us to produce groundbreaking therapeutic antibodies with powerful ADCC and CDC activity.



2. Destruction of target cell through a complement (a defense mechanism acquired by a multicellular organism to protect itself against foreign organisms)



World-Leading Human Antibody-Producing Mouse (KM Mouse™)

Created by combining Kyowa Hakko Kirin's Human Artificial Chromosome (HAC) technology and the human antibody-producing technology of Medarex, Inc. (currently Bristol-Myers Squibb Company) of the United States, the KM Mouse™ is recognized around the world as one of the most advanced technologies of its kind. KM Mouse™ technology has enabled the creation of mice that can generate fully human antibodies with the same diversity as naturally produced human antibodies, thus expanding the potential of clinical application.

Our dominant therapeutic antibody production technology enables efficient, high-quality production of therapeutic antibodies with the world's most advanced manufacturing equipment.



The investigational therapeutic antibody manufacturing facility that opened in March 2010 at the Bio Process Research and Development Laboratories in Takasaki, Gunma Prefecture will ultimately manufacture and supply bulk therapeutic antibodies. The facility comprises some of the world's largest culture tanks and purification equipment for recombinant mammalian cells.

Kyowa Hakko Kirin is implementing a category-based strategy in its four core therapeutic areas of nephrology, oncology, immunology/allergy and the central nervous system to accelerate research and development and maximize product value.

The category-based strategy is aimed at further enhancing our market competitiveness in Japan in the four therapeutic areas where we already have a strong presence. By strengthening coordination of functions from research and development to production and sales, we will steadily launch new drugs from our well-stocked pipeline. In addition, we will build an effective marketing organization with extensive expertise to maximize product value and earn the trust of health care professionals. The aim of these efforts is to reinforce our position as a major player in our therapeutic areas.



● NESP®

NESP® is a new long-acting erythropoiesis stimulating agent created through the application of cutting-edge genetic engineering and glycotecnology. By attaching new sugar chains to human erythropoietin (EPO), we successfully prolonged serum half-life. Unlike conventional EPO preparations for treatment in both predialysis and dialysis, NESP® enables suitable treatment because dosage frequency can be adjusted according to symptoms and frequency of hospital visits.

● ESPO®

ESPO® is a glycoprotein (human EPO) produced using genetic recombination technology. Its pharmacological effect of increasing erythrocytes enables its use as a renal anemia treatment in patients receiving autotransfusion and in CKD patients in predialysis and dialysis.



● REGPARA®

REGPARA® is a treatment for secondary hyperparathyroidism, a complication in dialysis patients. With a novel mechanism of action, it inhibits parathyroid hormone secretion and has brought advances in therapy, including proven effectiveness in patients who would have been candidates for surgery with conventional treatments.

We view the nephrology category as broadly encompassing not only the treatment of the various diseases that affect the kidneys, but also the alleviation of their symptoms and the investigation of their causes. As a leading company in nephrology, we are committed to helping everyone who is battling chronic kidney disease (CKD).

Nephrology

In this category, we provide value from the standpoint of patients to improve their quality of life, primarily through our products that are established in the market and have strong reputations. We are also advancing the development of new therapeutic antibodies to address unmet medical needs.



● ALLELOCK®

In addition to its potent and selective antihistamine activity, ALLELOCK® inhibits a wide range of mediators involved in allergic reactions. It has been shown to significantly improve the symptoms of allergic diseases such as urticaria and pollinosis. To accommodate patients of all ages, we have also made it available as an orally disintegrating tablet for ease of consumption and as granules for pediatric use.



● ASACOL®

ASACOL® is an oral enteric coated preparation containing the active ingredient 5-aminosalicylic acid (5-ASA, or mesalazine), the primary treatment for ulcerative colitis. The coating is applied for a pH-dependent controlled release. ASACOL® has obtained marketing approval and is used in more than 60 countries and regions, and is a market leader in the area of inflammatory bowel diseases.

Immunology/ Allergy



● Patanol®

Like ALLELOCK®, Patanol® antiallergic eyedrops use olopatadine hydrochloride as the active ingredient. The product is approved for sale in 105 countries, and has a leading market share in Japan and the United States.



● GRAN®

A protein produced using genetic recombination technology, GRAN® works to selectively increase the count of the white blood cells called neutrophils, as well as to increase their functional efficacy. This enables quick recovery from neutropenia caused by cancer chemotherapy and reduces the risk of infection, allowing more effective chemotherapy. It is also used to relieve congenital neutropenia or neutropenia occurring after hematopoietic stem-cell transplantation (such as bone-marrow transplants).

Oncology

In 2012, we launched the world's first therapeutic cancer antibody that applies our POTELLIGENT® technology for enhancement of antibody-dependent cellular cytotoxicity. We are aiming for further growth with additional new drug launches planned during the period of Medium-Term Business Plan – 2013 to 2015. Therapeutic antibodies will continue to be central to our efforts to address unmet medical needs in this category.

Treatments for Parkinson's disease will drive sales growth in the central nervous system area. We expect this to grow into our fourth major category, centered on NOURIAST® (generic name: istradefylline)*, which received manufacturing and marketing approval in Japan in March 2013.

* This drug is used to improve the "wearing off" phenomenon seen in Parkinson's disease patients undergoing treatment with levodopa medications. It is the world's first selective adenosine A_{2A} receptor antagonist approved as an antiparkinsonian agent.

Central Nervous System


● Apokyn®

A treatment for Parkinson's disease, Apokyn® is useful for rapidly improving "off" episodes in patients with motor complications who respond inadequately to conventional drug therapies.



● Permax®

Permax® is a dopamine D₁/D₂ receptor agonist for treatment of Parkinson's disease. It has pharmacological properties that demonstrate antiparkinsonian effects by acting on both D₁ and D₂ receptors.



● DEPAKENE®


DEPAKENE® is an antiepileptic agent with sodium valproate as its active ingredient, and has proven to be highly effective administered alone. It comes in various dosage forms for different clinical needs.

In support of our drive to become a global specialty pharmaceutical company, we are expanding our global business operations from drug discovery to development and marketing.

We are expanding our business operations in Europe, the United States and Asia. By organically integrating the infrastructure of ProStrakan, we will pursue global growth in accordance with business strategies tailored to each country and region. Moreover, we will actively promote translational research using our global research network to improve our success rate in clinical development.

Development in Europe and the United States is primarily handled by Kyowa Hakko Kirin Pharma, which coordinates with ProStrakan to boost development speed.

We conduct marketing in 12 countries in Europe and North America using ProStrakan's sales force.



North America and Europe

- | | | |
|--|-------------------------------|--------------------------|
| ① Kyowa Hakko Kirin America, Inc. ¹ | ⑤ ProStrakan Group plc | ⑨ ProStrakan Pharma B.V. |
| ② Kyowa Hakko Kirin Pharma, Inc. | ⑥ ProStrakan Pharma S.A.S | ⑩ ProStrakan S.r.l. |
| ③ BioWa, Inc. ² | ⑦ ProStrakan Farmaceutica SLU | ⑪ ProStrakan AB |
| ④ Kyowa Hakko Kirin California, Inc. | ⑧ ProStrakan Pharma GmbH | ⑫ ProStrakan Inc. |

1. U.S. holding company 2. Licensing of therapeutic antibodies and alliance activities intended to acquire promising external innovations and technologies

From Research to Marketing of Pharmaceuticals

In every step of the 6 stages of the process from research and development to manufacturing and marketing of pharmaceuticals, we exploit all our technology and know-how.



Using open innovation and translational research, we will vigorously conduct discovery research through our global network.



- Asia**
- 13 Kyowa Hakko Kirin China Pharmaceutical Co., Ltd.
 - 14 Kyowa Hakko Kirin Korea Co., Ltd.
 - 15 Kyowa Hakko Kirin (Taiwan) Co., Ltd.
 - 16 Kyowa Hakko Kirin (Hong Kong) Co., Ltd.
 - 17 Kyowa Hakko Kirin (Singapore) Pte. Ltd.
 - 18 Kyowa Hakko Kirin (Thailand) Co., Ltd.

We are building the robust operating foundation necessary for a global specialty pharmaceutical company.

By ensuring compliance at the global level and executing a CSR program that meets the expectations of society, we aim to be a trusted global specialty pharmaceutical company.


Management Philosophy and CSR of the Kyowa Hakko Kirin Group

In its Group Management Philosophy, the Kyowa Hakko Kirin Group promises “to contribute to the health and well-being of people around the world by creating new value through the pursuit of advances in life sciences and technologies.” Based on this philosophy, all employees perform their daily tasks in accordance with the Group’s Action Guidelines: “We will work together in a sincere and mutually respectful manner,” “We will take a forward-looking, energetic approach to change,” “We will do our utmost to add value and contribute to a brighter future around the world” and “We will always act with integrity in everything that we do.” We consider it part of our CSR to realize our management philosophy through activities consistent with these action guidelines.

CSR Promotion Policy

CSR activities have been reorganized from a global perspective as shown in the figure below according to the 7 core subjects defined in ISO 26000. Before the reorganization, our top priorities were “compliance” and “risk management” in terms of temporal urgency and, from a mid- to long-term perspective, “contribution through business activities” in response to changes in the social landscape in terms of organization and function. In addition to these two axes, the temporal axis and the axis of organization/function, the new policy includes the 7 core subjects proposed by ISO 26000 as the axis of social expectation.

Under this revised policy, more emphasis will be placed on dialogue with stakeholders as a means of strengthening our contribution to developing a sustainable society.



ISO 26000 is an international standard providing guidelines to help organizations meet their social responsibilities. Launched in November 2010, this guidance document offers a range of advice and applies to all types of organizations, including corporations, governments, schools and NGOs. It was prepared with input from a variety of stakeholders, including governments, corporations, workers, consumers, NGOs and experts from more than 40 organizations in over 90 countries, both in the developed and developing world. One of the reasons for undertaking such a large-scale project to establish this international standard for social responsibility is the increasing expectations held by stakeholders toward the international activities of various organizations.





Issues	Key Initiatives	
<p>—</p>	<ul style="list-style-type: none"> Enhanced corporate governance and the internal control system Used risk management system to prevent materialization of serious risks Held results presentation meetings, conference calls, lectures and other events for institutional investors and securities analysts 	<ul style="list-style-type: none"> Formulated business continuity plan for head office and key business sites Issued Message to Shareholders and Annual Report Conducted facility tours and held press conferences
<ul style="list-style-type: none"> Due diligence Human rights risk situations Avoidance of complicity Resolving grievances Discrimination and vulnerable groups Civil and political rights Economic, social and cultural rights Fundamental principles and rights at work Employment and employment relationships Conditions of work and social protection Social dialogue Health and safety at work Human development and training in the workplace 	<ul style="list-style-type: none"> Promoted hiring of people with disabilities Promoted diversity and inclusion Conducted human rights training throughout the Company Conducted human rights awareness survey Sent out president's message for Harassment Elimination Month and solicited human rights slogans during Human Rights Week Conducted thorough ethical reviews in research and development and protected human rights in clinical trials Provided childcare and nursing care support 	<ul style="list-style-type: none"> Supported employees' career development with programs such as the self-development support system Conducted global human resource development training Addressed mental health (conduct stress checks) Occupational safety and health Traffic safety measures (installed drive recorders in vehicles with higher accident risk, conducted risk prediction training) Conducted emergency drills at each site
<ul style="list-style-type: none"> Prevention of pollution Sustainable resource use Climate change mitigation and adaptation Protection of the environment, biodiversity and restoration of natural habitats 	<ul style="list-style-type: none"> Reduced CO₂ emissions Took measures to preserve biodiversity Promoted shift to hybrid vehicles in sales fleet Promoted Green Office Plan Reduced waste generation (maintained zero landfill waste) 	<ul style="list-style-type: none"> Promoted reuse and recycling (recover phosphate from fermentation wastewater) Reduced discharge of chemical substances Prevented air and water pollution Conducted environmental protection activities at each site
<ul style="list-style-type: none"> Anti-corruption Responsible political involvement Fair competition Promoting social responsibility in the value chain Respect for property rights 	<ul style="list-style-type: none"> Conducted questionnaire survey of suppliers on their CSR efforts Compliance education activities: Presented two corporate ethics lectures and conducted compliance training 	<ul style="list-style-type: none"> Received a certificate of conformity from the Center for Accreditation of Laboratory Animal Care and Use Provided education on the Anti-Monopoly Act and prevention of insider trading
<ul style="list-style-type: none"> Fair marketing, factual and unbiased information and fair contractual practices Protecting consumers' health and safety Sustainable consumption Consumer service, support, and complaint and dispute resolution Consumer data protection and privacy Access to essential services Education and awareness 	<ul style="list-style-type: none"> Supported DOPPS (an international study) to advance dialysis therapy Provided measures for preventing chronic kidney disease, pollinosis and other illnesses on our website Number of product-related inquiries handled by the Medical Information Office 	<ul style="list-style-type: none"> Renewed global website to enhance convenience for users Conducted training on Personal Information Protection Act by e-learning
<ul style="list-style-type: none"> Community involvement Education and culture Employment creation and skills development Technology development and access Wealth and income creation Health Social investment 	<ul style="list-style-type: none"> Promoted Kirin <i>Kizuna</i> (bonding) Relief-Support Project for post-disaster reconstruction in areas affected by the Great East Japan Earthquake Held science classes for young students Participated in community dialogue activities promoted by the Japan Responsible Care Council Interns accepted Supported La Jolla Institute for Allergy & Immunology, a nonprofit research institute 	<ul style="list-style-type: none"> Donated to the Kato Memorial Bioscience Foundation Participated in and donated to community events (Seoul Citizen Marathon to help pediatric cancer patients; marathon sponsored by support organization of Parkinson's disease patient groups in the U.S.) Distributed Braille calendars for the visually impaired Held health promotion lectures for local residents

Corporate Data


Company Name	Kyowa Hakko Kirin Co., Ltd.*
Established	July 1, 1949
	* Company name changed from Kyowa Hakko Kogyo Co., Ltd. following merger with Kirin Pharma Company, Limited on October 1, 2008.
Capital	¥26,745 million (As of December 31, 2012)
Number of Employees	7,243 (Consolidated basis, as of December 31, 2012)
President & CEO	Nobuo Hanai
Head Office	Ohtemachi Building, 1-6-1 Ohtemachi, Chiyoda-ku, Tokyo 100-8185, Japan TEL: +81-3-3282-0007 FAX: +81-3-3284-1968
Consolidated Sales	¥333,158 million (Year ended December 31, 2012)
Main Business	Kyowa Hakko Kirin is engaged in the manufacturing and marketing of medical products and pharmaceuticals. As the holding company of the Kyowa Hakko Kirin Group, it manages the business activities in the Bio-Chemicals business.
Parent Company	Kirin Holdings Company, Limited

Kyowa Hakko Kirin Group

Group Management Philosophy The Kyowa Hakko Kirin Group companies strive to contribute to the health and well-being of people around the world by creating new value through the pursuit of advances in life sciences and technologies.

Group Vision The Kyowa Hakko Kirin Group aims to be a world-class R&D-focused life sciences group of companies, based on biotechnology and with the pharmaceutical business at its core.

Group Organization



Main Business Offices

Our headquarters in the heart of Tokyo oversees and coordinates the operations of the 65 domestic sales offices as well as of the five state-of-the-art research laboratories that drive our Pharmaceuticals business and the plants that are fully compliant with international standards of quality control. Providing total support in every stage from development to marketing, Kyowa Hakko Kirin Co., Ltd. is ready to meet any challenge.

Branch Offices

Sapporo Branch

Davinci Sapporo Park Front 5F, 7-1-1 Odorinishi, Chuo-ku, Sapporo-shi, Hokkaido 060-0042
TEL: +81-11-261-3127 FAX: +81-11-261-2584

Tohoku Branch

Sendai Hashimoto Building 9F, 27-21 Tachi-machi, Aoba-ku, Sendai-shi, Miyagi 980-0822
TEL: +81-22-262-7691 FAX: +81-22-223-6563

Tokyo Branch, Chiba-Saitama Branch, Kita-Kanto Branch, Koshinetsu Branch, Yokohama Branch

Riverside Yomiuri Building 13F, 36-2 Nihonbashi-Hakozaki-cho, Chuo-ku, Tokyo 103-8503
TEL: +81-3-5641-8600 FAX: +81-3-5641-8681

Nagoya Branch

CRD Marunouchi 10F, 3-17-13 Marunouchi, Naka-ku, Nagoya-shi, Aichi 460-0002
TEL: +81-52-962-1091 FAX: +81-52-962-5243

Osaka Branch, Keiji-Hokuriku Branch

Dojima Avanza 14F, 1-6-20 Dojima, Kita-ku, Osaka-shi, Osaka 530-8280
TEL: +81-6-6346-6900 FAX: +81-6-6346-6825

Chugoku Branch

Hiroshima Inarimachi Daiichi Seimei Building 7F, 2-16 Inari-machi, Minami-ku, Hiroshima-shi, Hiroshima 732-0827
TEL: +81-82-262-6680 FAX: +81-82-262-5242

Shikoku Branch

Matsuyama Daiichi Seimei Building 9F, 3-2-11 Ichiban-cho, Matsuyama-shi, Ehime 790-0001
TEL: +81-89-945-1288 FAX: +81-89-932-1237

Kyushu Branch

Fukuoka Center Building 13F, 2-2-1 Hakataekimae, Hakata-ku, Fukuoka-shi, Fukuoka 812-8663
TEL: +81-92-473-5631 FAX: +81-92-475-4573

Research Laboratories

Tokyo Research Park

3-6-6 Asahi-machi, Machida-shi, Tokyo 194-8533
TEL: +81-42-725-2555 FAX: +81-42-726-8330

Fuji Research Park

1188 Shimotogari, Nagaizumi-cho, Sunto-gun, Shizuoka 411-8731
TEL: +81-55-989-2004 FAX: +81-55-986-7430

Bio Process Research and Development Laboratories

100-1 Hagiwara-machi, Takasaki-shi, Gunma 370-0013
TEL: +81-27-353-2011 FAX: +81-27-353-2123

Drug Formulation Research and Development Laboratories

1188 Shimotogari, Nagaizumi-cho, Sunto-gun, Shizuoka 411-8731
TEL: +81-55-989-2004 FAX: +81-55-986-7430

Chemical Process Research and Development Laboratories

1-1-53 Takasu-cho, Sakai-ku, Sakai-shi, Osaka 590-8554
TEL: +81-72-223-5554 FAX: +81-72-227-7214

Plants

Takasaki Plant

100-1 Hagiwara-machi, Takasaki-shi, Gunma 370-0013
TEL: +81-27-353-2011 FAX: +81-27-353-2123

Fuji Plant

1188 Shimotogari, Nagaizumi-cho, Sunto-gun, Shizuoka 411-8731
TEL: +81-55-986-7600 FAX: +81-55-989-2091

Yokkaichi Plant

2-3 Daikyo-cho, Yokkaichi-shi, Mie 510-8502
TEL: +81-59-331-5149 FAX: +81-59-331-5177

Sakai Plant

1-1-53 Takasu-cho, Sakai-ku, Sakai-shi, Osaka 590-8554
TEL: +81-72-223-5554 FAX: +81-72-227-7214

Ube Plant

2547-3 Fujimagari, Ube-shi, Yamaguchi 755-8501
TEL: +81-836-22-5508 FAX: +81-836-22-5534

Main Group Companies

Our business is global in vision and scale. We are working in close collaboration with our group companies in the pharmaceutical and biochemical industries to bring exciting new products to markets around the world.

Japan

Kyowa Medex Co., Ltd.

Harumi Island Triton Square Tower X-4F, 1-8-10 Harumi, Chuo-ku, Tokyo 104-6004
TEL: +81-3-6219-7600 FAX: +81-3-6219-7614

Kyowa Medical Promotion Co., Ltd.

Riverside Yomiuri Building, 36-2 Nihonbashi-Hakozaki-cho, Chuo-ku, Tokyo 103-0015
TEL: +81-3-5641-8658 FAX: +81-3-5641-8697

Overseas

U.S.A.

BioWa, Inc. / California, U.S.A.

9420 Athena Circle, La Jolla, CA 92037, U.S.A.
TEL: +1-858-952-7200 FAX: +1-858-952-7001

Kyowa Hakko Kirin Pharma, Inc. / Princeton, U.S.A.

212 Carnegie Center, Suite 101, Princeton, NJ 08540, U.S.A.
TEL: +1-609-919-1100 FAX: +1-609-919-1111

FUJIFILM KYOWA KIRIN BIOLOGICS Co., Ltd.

Ohtemachi Building 9F, 1-6-1 Ohtemachi, Chiyoda-ku, Tokyo 100-8185
TEL: +81-3-3282-0700 FAX: +81-3-3282-0611

Kyowa Hakko Bio Co., Ltd.

Ohtemachi Building 5F, 1-6-1 Ohtemachi, Chiyoda-ku, Tokyo 100-8185
TEL: +81-3-3282-0974 FAX: +81-3-3284-1802

Kyowa Hakko Kirin America, Inc. / Princeton, U.S.A.

212 Carnegie Center, Suite 101, Princeton, NJ 08540, U.S.A.
TEL: +1-609-580-7400 FAX: +1-609-919-1111

Kyowa Hakko Kirin California, Inc. / California, U.S.A.

9420 Athena Circle, La Jolla, CA 92037, U.S.A.
TEL: +1-858-952-7000 FAX: +1-858-952-7001

Europe

ProStrakan Group plc / Scotland, United Kingdom

Galabank Business Park, Galashiels TD1 1QH, United Kingdom
TEL: +44-1896-664000 FAX: +44-1896-664001

Asia

Kyowa Hakko Kirin China Pharmaceutical Co., Ltd. / Shanghai, China

970 Long Dong Road, Z.J. High-Tech Park, Pudong New Area, Shanghai 201203, China
TEL: +86-21-5080-0909 FAX: +86-21-5080-0026

Kyowa Hakko Kirin Korea Co., Ltd. / Seoul, Republic of Korea

5F, Poonglim Bldg., 124, Teheran-ro, Gangnam-gu, Seoul 135-784, Republic of Korea
TEL: +82-2-3471-4321 FAX: +82-2-3471-4322

Kyowa Hakko Kirin (Taiwan) Co., Ltd. / Taipei, Taiwan

9F, No. 44, Sec 2, Chung Shan N. Road, Taipei 10448, Taiwan
TEL: +886-2-2564-2800 FAX: +886-2-2560-1667

Kyowa Hakko Kirin (Hong Kong) Co., Ltd. / Hong Kong, China

Unit B, 13/F, Manulife Tower, 169 Electric Road, North Point, Hong Kong, China
TEL: +852-2956-0828 FAX: +852-2956-1627

Kyowa Hakko Kirin (Singapore) Pte. Ltd. / Singapore

260, Orchard Road, #07-06 The Heeren, 238855, Singapore
TEL: +65-6836-3991 FAX: +65-6836-3928

Kyowa Hakko Kirin (Thailand) Co., Ltd. / Bangkok, Thailand

20F, United Center Bldg., 323 Silom Road, Silom, Bangrak, Bangkok 10500, Thailand
TEL: +66-2631-2126 FAX: +66-2631-2125

Kyowa Hakko Kirin Co., Ltd.

Ohtemachi Building, 1-6-1 Ohtemachi, Chiyoda-ku, Tokyo 100-8185, Japan
TEL: +81-3-3282-0007 FAX: +81-3-3284-1968 <http://www.kyowa-kirin.com>



April 2013 / Printed in Japan